BON NATURAL LIFE LTD-A (BON) Fundamental Analysis & Valuation

NASDAQ:BON • KYG144922047

1.62 USD
0 (0%)
Last: Mar 4, 2026, 01:48 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This BON fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to BON. BON was compared to 83 industry peers in the Chemicals industry. BON may be in some trouble as it scores bad on both profitability and health. BON does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

2

1. BON Profitability Analysis

1.1 Basic Checks

  • In the past year BON was profitable.
  • In the past year BON had a positive cash flow from operations.
  • BON had positive earnings in 4 of the past 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: BON reported negative operating cash flow in multiple years.
BON Yearly Net Income VS EBIT VS OCF VS FCFBON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M

1.2 Ratios

  • The Return On Assets of BON (-2.34%) is worse than 62.65% of its industry peers.
  • BON has a Return On Equity of -3.47%. This is comparable to the rest of the industry: BON outperforms 44.58% of its industry peers.
Industry RankSector Rank
ROA -2.34%
ROE -3.47%
ROIC N/A
ROA(3y)2.72%
ROA(5y)7.5%
ROE(3y)3.46%
ROE(5y)9.83%
ROIC(3y)N/A
ROIC(5y)N/A
BON Yearly ROA, ROE, ROICBON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30

1.3 Margins

  • BON has a Gross Margin of 20.78%. This is in the lower half of the industry: BON underperforms 62.65% of its industry peers.
  • In the last couple of years the Gross Margin of BON has declined.
  • The Profit Margin and Operating Margin are not available for BON so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 20.78%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.96%
GM growth 5Y-6.16%
BON Yearly Profit, Operating, Gross MarginsBON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. BON Health Analysis

2.1 Basic Checks

  • BON does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • BON has more shares outstanding than it did 1 year ago.
  • BON has more shares outstanding than it did 5 years ago.
  • BON has a worse debt/assets ratio than last year.
BON Yearly Shares OutstandingBON Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M
BON Yearly Total Debt VS Total AssetsBON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

  • BON has an Altman-Z score of 0.97. This is a bad value and indicates that BON is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of BON (0.97) is worse than 73.49% of its industry peers.
  • A Debt/Equity ratio of 0.19 indicates that BON is not too dependend on debt financing.
  • With an excellent Debt to Equity ratio value of 0.19, BON belongs to the best of the industry, outperforming 80.72% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Altman-Z 0.97
ROIC/WACCN/A
WACC8.67%
BON Yearly LT Debt VS Equity VS FCFBON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M

2.3 Liquidity

  • BON has a Current Ratio of 1.74. This is a normal value and indicates that BON is financially healthy and should not expect problems in meeting its short term obligations.
  • BON has a worse Current ratio (1.74) than 60.24% of its industry peers.
  • BON has a Quick Ratio of 1.61. This is a normal value and indicates that BON is financially healthy and should not expect problems in meeting its short term obligations.
  • BON has a Quick ratio of 1.61. This is in the better half of the industry: BON outperforms 67.47% of its industry peers.
Industry RankSector Rank
Current Ratio 1.74
Quick Ratio 1.61
BON Yearly Current Assets VS Current LiabilitesBON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. BON Growth Analysis

3.1 Past

  • The earnings per share for BON have decreased strongly by -96.73% in the last year.
  • BON shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -21.70%.
  • The Revenue has been growing slightly by 0.49% on average over the past years.
EPS 1Y (TTM)-96.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.33%
Revenue 1Y (TTM)-21.7%
Revenue growth 3Y-14.54%
Revenue growth 5Y0.49%
Sales Q2Q%-21.52%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • Based on estimates for the next years, BON will show a quite strong growth in Revenue. The Revenue will grow by 13.43% on average per year.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year18.82%
Revenue Next 2Y17.22%
Revenue Next 3Y15.15%
Revenue Next 5Y13.43%

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BON Yearly Revenue VS EstimatesBON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 20M 40M 60M 80M 100M
BON Yearly EPS VS EstimatesBON Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 50 100 150

More info and screens

Find the best growth stocksShow best growing peers

1

4. BON Valuation Analysis

4.1 Price/Earnings Ratio

  • BON is valuated rather expensively with a Price/Earnings ratio of 18.00.
  • 63.86% of the companies in the same industry are more expensive than BON, based on the Price/Earnings ratio.
  • Compared to an average S&P500 Price/Earnings ratio of 26.83, BON is valued a bit cheaper.
Industry RankSector Rank
PE 18
Fwd PE N/A
BON Price Earnings VS Forward Price EarningsBON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BON Per share dataBON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BON Dividend Analysis

5.1 Amount

  • No dividends for BON!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BON Fundamentals: All Metrics, Ratios and Statistics

BON NATURAL LIFE LTD-A

NASDAQ:BON (3/4/2026, 1:48:41 PM)

1.62

0 (0%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)01-23
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap10.00M
Revenue(TTM)18.67M
Net Income(TTM)-1.99M
Analysts0
Price TargetN/A
Short Float %0.19%
Short Ratio0.16
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 18
Fwd PE N/A
P/S 0.54
P/FCF N/A
P/OCF 70.84
P/B 0.17
P/tB 0.2
EV/EBITDA N/A
EPS(TTM)0.09
EY5.56%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.6
FCFYN/A
OCF(TTM)0.02
OCFY1.41%
SpS3.03
BVpS9.33
TBVpS8.29
PEG (NY)N/A
PEG (5Y)N/A
Graham Number4.35
Profitability
Industry RankSector Rank
ROA -2.34%
ROE -3.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 20.78%
FCFM N/A
ROA(3y)2.72%
ROA(5y)7.5%
ROE(3y)3.46%
ROE(5y)9.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.96%
GM growth 5Y-6.16%
F-Score3
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 919.08%
Cap/Sales 53.54%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.74
Quick Ratio 1.61
Altman-Z 0.97
F-Score3
WACC8.67%
ROIC/WACCN/A
Cap/Depr(3y)348.17%
Cap/Depr(5y)1058.3%
Cap/Sales(3y)19.2%
Cap/Sales(5y)18.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-96.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.33%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-21.7%
Revenue growth 3Y-14.54%
Revenue growth 5Y0.49%
Sales Q2Q%-21.52%
Revenue Next Year18.82%
Revenue Next 2Y17.22%
Revenue Next 3Y15.15%
Revenue Next 5Y13.43%
EBIT growth 1Y-186.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-27.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y101.83%
OCF growth 3YN/A
OCF growth 5Y-44.35%

BON NATURAL LIFE LTD-A / BON FAQ

Can you provide the ChartMill fundamental rating for BON NATURAL LIFE LTD-A?

ChartMill assigns a fundamental rating of 2 / 10 to BON.


Can you provide the valuation status for BON NATURAL LIFE LTD-A?

ChartMill assigns a valuation rating of 1 / 10 to BON NATURAL LIFE LTD-A (BON). This can be considered as Overvalued.


How profitable is BON NATURAL LIFE LTD-A (BON) stock?

BON NATURAL LIFE LTD-A (BON) has a profitability rating of 2 / 10.